Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer

被引：58

作者：

Gower, Arjan ^{[1
]}

Wang, Yisong ^{[1
]}

Giaccone, Giuseppe ^{[1
]}

机构：

[1] Georgetown Univ, Washington, DC 20057 USA

来源：

JOURNAL OF MOLECULAR MEDICINE-JMM | 2014年 / 92卷 / 07期

关键词：

Non-small-cell lung cancer; Oncogenic drivers; TKIs; RTKs; Acquired resistance; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; MOLECULAR TESTING GUIDELINE; OF-AMERICAN-PATHOLOGISTS; EML4-ALK FUSION GENE; OPEN-LABEL; PHASE-III; ALK INHIBITOR; EGFR MUTATION; GEFITINIB RESISTANCE;

D O I：

10.1007/s00109-014-1165-y

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical benefit. As the genomic classification of lung cancer continues to evolve and as the mechanisms of acquired resistance to targeted therapies become elucidated and more improved target-specific drugs come into sight, the future will see more promising results from the clinic through the development of new therapeutic strategies to overcome, or prevent the development of, resistance for lung cancer patients.

引用

页码：697 / 707

页数：11

共 117 条

[81] A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors [J].

Sasaki, Takaaki ;

Koivunen, Jussi ;

Ogino, Atsuko ;

Yanagita, Masahiko ;

Nikiforow, Sarah ;

Zheng, Wei ;

Lathan, Christopher ;

Marcoux, J. Paul ;

Du, Jinyan ;

Okuda, Katsuhiro ;

Capelletti, Marzia ;

Shimamura, Takeshi ;

Ercan, Dalia ;

Stumpfova, Magda ;

Xiao, Yun ;

Weremowicz, Stanislawa ;

Butaney, Mohit ;

Heon, Stephanie ;

Wilner, Keith ;

Christensen, James G. ;

Eck, Michel J. ;

Wong, Kwok-Kin ;

Lindeman, Neal ;

Gray, Nathanael S. ;

Rodig, Scott J. ;

Jaenne, Pasi A. .

CANCER RESEARCH, 2011, 71 (18) :6051-6060

[82] Targeted cancer therapy [J].

Sawyers, C .

NATURE, 2004, 432 (7015) :294-297

[83] Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer [J].

Scagliotti, GV ;

De Marinis, F ;

Rinaldi, M ;

Crinò, L ;

Gridelli, C ;

Ricci, S ;

Matano, E ;

Boni, C ;

Marangolo, M ;

Failla, G ;

Altavilla, G ;

Adamo, V ;

Ceribelli, A ;

Clerici, M ;

Di Costanzo, F ;

Frontini, L ;

Tonato, M .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4285-4291

[84] Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J].

Schiller, JH ;

Harrington, D ;

Belani, CP ;

Langer, C ;

Sandler, A ;

Krook, J ;

Zhu, JM ;

Johnson, DH .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :92-98

[85] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations [J].

Sequist, Lecia V. ;

Yang, James Chih-Hsin ;

Yamamoto, Nobuyuki ;

O'Byrne, Kenneth ;

Hirsh, Vera ;

Mok, Tony ;

Geater, Sarayut Lucien ;

Orlov, Sergey ;

Tsai, Chun-Ming ;

Boyer, Michael ;

Su, Wu-Chou ;

Bennouna, Jaafar ;

Kato, Terufumi ;

Gorbunova, Vera ;

Lee, Ki Hyeong ;

Shah, Riyaz ;

Massey, Dan ;

Zazulina, Victoria ;

Shahidi, Mehdi ;

Schuler, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3327-+

[86] Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors [J].

Sequist, Lecia V. ;

Waltman, Belinda A. ;

Dias-Santagata, Dora ;

Digumarthy, Subba ;

Turke, Alexa B. ;

Fidias, Panos ;

Bergethon, Kristin ;

Shaw, Alice T. ;

Gettinger, Scott ;

Cosper, Arjola K. ;

Akhavanfard, Sara ;

Heist, Rebecca S. ;

Temel, Jennifer ;

Christensen, James G. ;

Wain, John C. ;

Lynch, Thomas J. ;

Vernovsky, Kathy ;

Mark, Eugene J. ;

Lanuti, Michael ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (75)

[87] CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study [J].

Seto, Takashi ;

Kiura, Katsuyuki ;

Nishio, Makoto ;

Nakagawa, Kazuhiko ;

Maemondo, Makoto ;

Inoue, Akira ;

Hida, Toyoaki ;

Yamamoto, Nobuyuki ;

Yoshioka, Hiroshige ;

Harada, Masao ;

Ohe, Yuichiro ;

Nogami, Naoyuki ;

Takeuchi, Kengo ;

Shimada, Tadashi ;

Tanaka, Tomohiro ;

Tamura, Tomohide .

LANCET ONCOLOGY, 2013, 14 (07) :590-598

[88] The evolving genomic classification of lung cancer [J].

Shames, David S. ;

Wistuba, Ignacio I. .

JOURNAL OF PATHOLOGY, 2014, 232 (02) :121-133

[89]

Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI [10.1056/NEJMoa1311107, 10.1056/NEJMc1404894]

[90] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer [J].

Shaw, Alice T. ;

Kim, Dong-Wan ;

Nakagawa, Kazuhiko ;

Seto, Takashi ;

Crino, Lucio ;

Ahn, Myung-Ju ;

De Pas, Tommaso ;

Besse, Benjamin ;

Solomon, Benjamin J. ;

Blackhall, Fiona ;

Wu, Yi-Long ;

Thomas, Michael ;

O'Byrne, Kenneth J. ;

Moro-Sibilot, Denis ;

Camidge, D. Ross ;

Mok, Tony ;

Hirsh, Vera ;

Riely, Gregory J. ;

Iyer, Shrividya ;

Tassell, Vanessa ;

Polli, Anna ;

Wilner, Keith D. ;

Jaenne, Pasi A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25) :2385-2394

← 3 4 5 6 7 8 9 10 11 12 →